Characterization and Genetic Analyses of New Genes Coding for NOD2 Interacting Proteins von Thiébaut, Raphaële, Esmiol, Sophie, Lecine, Patrick, Mahfouz, Batoul, Hermant, Aurelie, Nicoletti, Cendrine, Parnis, Stephane, Perroy, Julie, Borg, Jean-Paul, Pascoe, Leigh, Hugot, Jean-Pierre, Ollendorff, Vincent

Volltext

Enterocytin: A new specific enterocyte marker bearing a B30.2-like domain von Parnis, Stéphane, Nicoletti, Cendrine, Ollendorff, Vincent, Massey-Harroche, Dominique

Volltext

Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial von Kelley, RobinKate, Ryoo, Baek-Yeol, Merle, Philippe, Park, Joong-Won, Bolondi, Luigi, Chan, Stephen L., Lim, HoYeong, Baron, Ari D., Parnis, Francis, Knox, Jennifer, Cattan, Stéphane, Yau, Thomas, Lougheed, Julie C., Milwee, Steven, El-Khoueiry, Anthony B., Cheng, Ann-Lii, Meyer, Tim, Abou-Alfa, Ghassan K.

Volltext

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma von Choueiri, Toni K, Tomczak, Piotr, Park, Se Hoon, Venugopal, Balaji, Ferguson, Thomas, Chang, Yen-Hwa, Hajek, Jaroslav, Symeonides, Stefan N, Lee, Jae Lyun, Sarwar, Naveed, Thiery-Vuillemin, Antoine, Gross-Goupil, Marine, Mahave, Mauricio, Haas, Naomi B, Sawrycki, Piotr, Gurney, Howard, Chevreau, Christine, Melichar, Bohuslav, Kopyltsov, Evgeniy, Alva, Ajjai, Burke, John M, Doshi, Gurjyot, Topart, Delphine, Oudard, Stephane, Hammers, Hans, Kitamura, Hiroshi, Bedke, Jens, Perini, Rodolfo F, Zhang, Pingye, Imai, Kentaro, Willemann-Rogerio, Jaqueline, Quinn, David I, Powles, Thomas

Volltext

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer von Fizazi, Karim, Shore, Neal, Tammela, Teuvo L, Ulys, Albertas, Vjaters, Egils, Polyakov, Sergey, Jievaltas, Mindaugas, Luz, Murilo, Alekseev, Boris, Kuss, Iris, Kappeler, Christian, Snapir, Amir, Sarapohja, Toni, Smith, Matthew R

Volltext

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, doubl... von Tomczak, Piotr, Venugopal, Balaji, Ferguson, Thomas, Chang, Yen-Hwa, Gross-Goupil, Marine, Burgents, Joseph E, Xu, Lei, Imai, Kentaro, Choueiri, Toni K, Venugopal, Balaji, Lin, Tzu-Ping, Symeonides, Stefan N., Sawrycki, Piotr, Haas, Naomi B., Sarwar, Naveed, Thiery-Vuillemin, Antoine, Gross-Goupil, Marine, Doshi, Gurjyot, Melichar, Bohuslav, Kopyltsov, Evgeniy, Hammers, Hans-Joerg, Menezes, Juliana de Janoski, Winquist, Eric W., Hamzaj, Alketa, Karaszewska, Boguslawa, Lipatov, Oleg N., McDermott, David, Kochuparambil, Samith T., Davis, Ian D., Peltola, Katriina, Sabbatini, Roberto, Shkolnik, Michail I., McCune, Steven, Yeung, Carrie, Laguerre, Brigitte, Fomin, Eugeniy A., Zakharia, Yousef, Yorio, Jeffrey T., Yanez Ruiz, Eduardo, Kimura, Go, Nishimura, Kazuo, Masumori, Naoya, Kato, Haruaki, Sala Gonzalez, Nuria, Chiu, Kun-Yuan, Atkins, Michael B., Heath, Elisabeth, Feyerabend, Susan, Numakura, Kazuyuki, Zukov, Ruslan, Maroto Rey, Pablo Jose, Chang, Chao-Hsiang, Vengalil, Salil, Waddell, Tom S., Hauke, Ralph, Jayram, Gautam, Estay, Angela, Rubiano, Juan Andres, Anai, Satoshi, Tsunemori, Hiroyuki, Sikora-Kupis, Bozena, Gunderson, Elizabeth, Koletsky, Alan, Chen, Kevin, Agrawal, Manish, Parnis, Francis, Barbosa, Fernando Maciel, Faucher, Genevieve, Iqbal, Nayyer, Hanna, Nawar, Ibanez, Carolina, Manneh, Ray, Holeckova, Petra, Ronkainen, Hanna, Abadie-Lacourtoisie, Sophie, Goebell, Peter J., Hoefner, Thomas, Schultze-Seemann, Wolfgang, Yokomizo, Akira, Matsukawa, Yoshihisa, Murakami, Yoji, Kim, Miso, Szczylik, Cezary, Humphreys, Alison C., Kumar, Birendra, Karam, Jose Antonio, Fleming, Mark, Zarba, Juan Jose, Leiva, Viviana E., Antonio Junior, Joao Neif, Rocha, Roberto Odebrecht, Muniz, David, Brust, Leandro, Graham, Jeffrey, Borchiellini, Delphine, McDermott, Ray, Miura, Yuji, Prow, Debra M., Hashemi-Sadraei, Neda, Kendall, Stephan D.

Volltext

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial von Smith, Matthew R, Scher, Howard I, Sandhu, Shahneen, Efstathiou, Eleni, Lara, Primo N, Yu, Evan Y, Chi, Kim N, Ståhl, Olof, Olmos, David, Danila, Daniel C, Espina, Byron M, Zhao, Xin, Urtishak, Karen A, Francis, Peter, Lopez-Gitlitz, Angela, Parnis, Francis, Horvath, Lisa G., Steer, Christopher, Marx, Gavin, Sandhu, Shahneen, Ferguson, Thomas, Luyten, Daisy, Lumen, Nicolaas, Dirix, Luc, Goeminne, Jean-Charles, Gil, Thierry, Vulsteke, Christof, Kussumoto, Celio, Franke, Fabio A., Martinelli de Oliveira, Fabricio Augusto, Pereira de Santana Gomes, Andrea Juliana, Preto, Daniel D'Almeida, Zucca, Luis Eduardo, Borges, Giuliano Santos, Murad, Andre M., Saad, Fred, Chi, Kim N., Fradet, Yves, Fleshner, Neil E., Emmenegger, Urban, Brasso, Klaus, Culine, Stephane, Thiery-Vuillemin, Antoine, Joly, Florence, Fléchon, Aude, Hilgers, Werner, Borchiellini, Delphine, Barthélémy, Philippe, Berger, Raanan, Mermershtain, Wilmosh, Peer, Avivit, Sella, Avishay, Voortman, Johannes, Aarts, Maureen J., Gietema, Jourik A., Choi, Young-Deuk, Gafanov, Rustem A., Kopyltsov, Evgeniy, Carles, Joan, Mellado, Begoña, Maroto, José Pablo, García-Donás, Jesús, Rodríguez Moreno, Juan Francisco, Durán, Ignacio, Pérez-Valderrama, Begoña, Castro, Elena, Olmos, David, Méndez-Vidal, María José, Muñoz-Langa, José, Herranz, Urbano Anido, Puente Vázquez, Javier, Castellanos, Enrique, Hellström, Martin, Widmark, Anders, Lissbrant, Ingela Franck, Jellvert, Åsa, Külich, Cecilia, Blom, René, Kang, Chih-Hsiung, Ou, Yen-Chuan, Wang, Shian-Shiang, Attard, Gerhardt, Bahl, Amit, Kellati, Prasad, Parikh, Omi, Srinivasan, Rajaguru, Lester, Jason F., Staffurth, John N., Cheng, Heather H., Efstathiou, Eleni, Pilié, Patrick G., George, Daniel J., Karsh, Lawrence I., Kelly, W. Kevin, Danila, Daniel C., Smith, Matthew R., Heath, Elisabeth I., Vaishampayan, Ulka N., Emamekhoo, Hamid, Pinski, Jacek K.

Volltext

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma von Choueiri, Toni K., Tomczak, Piotr, Park, Se Hoon, Venugopal, Balaji, Ferguson, Tom, Symeonides, Stefan N., Hajek, Jaroslav, Chang, Yen-Hwa, Lee, Jae-Lyun, Sarwar, Naveed, Haas, Naomi B., Gurney, Howard, Sawrycki, Piotr, Mahave, Mauricio, Gross-Goupil, Marine, Zhang, Tian, Burke, John M., Doshi, Gurjyot, Melichar, Bohuslav, Kopyltsov, Evgeniy, Alva, Ajjai, Oudard, Stephane, Topart, Delphine, Hammers, Hans, Kitamura, Hiroshi, McDermott, David F., Silva, Adriano, Winquist, Eric, Cornell, Jerry, Elfiky, Aymen, Burgents, Joseph E., Perini, Rodolfo F., Powles, Thomas

Volltext

Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepat... von Kelley, Robin Kate, Ryoo, Baek-Yeol, Merle, Philippe, Park, Joong-Won, Bolondi, Luigi, Chan, Stephen Lam, Lim, Ho Yeong, Baron, Ari David, Parnis, Francis, Knox, Jennifer, Cattan, Stéphane, Yau, Thomas Cheung, Lougheed, Julie, Milwee, Steven, El-Khoueiry, Anthony, Cheng, Ann-Lii, Meyer, Tim, Abou-Alfa, Ghassan K.

Volltext

Analysis of two poor prognosis subgroups in ACIS evaluating apalutamide + abiraterone acetate plus prednisone (APA + AAP) versus placebo (PBO) + AAP in metastatic castration-resist... von Saad, Fred, Efstathiou, Eleni, Attard, Gerhardt, Flaig, Thomas W., Franke, Fabio, Goodman, Oscar, Oudard, Stephane, Steuber, Thomas, Suzuki, Hiroyoshi, Pieczonka, Christopher Michael, Parnis, Francis, Wu, Daphne, Yeruva, Kesav, De Porre, Peter, Brookman-May, Sabine Doris, Li, Susan, Li, Jinhui, Mundle, Suneel, McCarthy, Sharon Anne, Rathkopf, Dana E.

Volltext